DaVita Inc. (NYSE:DVA) Short Interest Update

DaVita Inc. (NYSE:DVA) was the recipient of a significant decline in short interest during the month of October. As of October 15th, there was short interest totalling 4,300,000 shares, a decline of 14.9% from the September 30th total of 5,050,000 shares. Approximately 5.4% of the shares of the stock are sold short. Based on an average daily volume of 711,500 shares, the days-to-cover ratio is presently 6.0 days.

Analysts Set New Price Targets

A number of brokerages have issued reports on DVA. Truist Financial upped their price objective on DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research report on Monday, October 7th. Barclays raised their price target on DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a research report on Thursday. TD Cowen boosted their price objective on shares of DaVita from $139.00 to $150.00 and gave the company a “hold” rating in a research report on Wednesday, July 24th. Bank of America raised their target price on shares of DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a report on Wednesday, August 7th. Finally, UBS Group upped their price target on shares of DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a report on Thursday, August 8th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $161.80.

Insider Transactions at DaVita

In related news, insider Kathleen Alyce Waters sold 7,857 shares of the stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the completion of the transaction, the insider now directly owns 83,011 shares of the company’s stock, valued at approximately $12,137,038.31. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, CEO Javier Rodriguez sold 32,176 shares of the business’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $155.93, for a total value of $5,017,203.68. Following the sale, the chief executive officer now directly owns 905,659 shares in the company, valued at $141,219,407.87. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Kathleen Alyce Waters sold 7,857 shares of the company’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the sale, the insider now owns 83,011 shares in the company, valued at $12,137,038.31. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 173,482 shares of company stock valued at $27,387,069. 2.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On DaVita

A number of institutional investors and hedge funds have recently bought and sold shares of DVA. Blue Trust Inc. lifted its position in shares of DaVita by 58.6% in the 2nd quarter. Blue Trust Inc. now owns 211 shares of the company’s stock worth $29,000 after purchasing an additional 78 shares during the period. Family Firm Inc. bought a new stake in DaVita during the 2nd quarter valued at $43,000. Versant Capital Management Inc increased its holdings in shares of DaVita by 90.6% in the 2nd quarter. Versant Capital Management Inc now owns 326 shares of the company’s stock valued at $45,000 after acquiring an additional 155 shares during the period. Friedenthal Financial bought a new position in shares of DaVita in the 2nd quarter worth $48,000. Finally, Point72 Hong Kong Ltd purchased a new stake in shares of DaVita during the 2nd quarter worth $68,000. 90.12% of the stock is owned by institutional investors.

DaVita Trading Down 0.5 %

Shares of DVA traded down $0.65 during trading hours on Thursday, reaching $140.57. 790,406 shares of the company traded hands, compared to its average volume of 817,066. The firm has a market cap of $11.79 billion, a price-to-earnings ratio of 14.94, a PEG ratio of 0.90 and a beta of 0.87. DaVita has a 12-month low of $76.17 and a 12-month high of $168.50. The stock’s fifty day moving average price is $158.21 and its 200 day moving average price is $146.02. The company has a current ratio of 1.16, a quick ratio of 1.12 and a debt-to-equity ratio of 9.94.

DaVita (NYSE:DVA) last issued its earnings results on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). DaVita had a return on equity of 77.00% and a net margin of 6.86%. The company had revenue of $3.26 billion during the quarter, compared to the consensus estimate of $3.25 billion. During the same quarter in the prior year, the company earned $2.85 earnings per share. DaVita’s revenue was up 4.6% on a year-over-year basis. Sell-side analysts forecast that DaVita will post 9.99 earnings per share for the current year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.